Abstract
The overexpression of GAS1 (Growth Arrest Specific 1) in glioma cells induces cell cycle arrest and apoptosis. We previously demonstrated that the apoptotic process set off by GAS1 is caused by its capacity to inhibit the Glial cell-derived neurotrophic factor (GDNF)-mediated intracellular survival signaling pathway. Whereas on the other hand, PTEN is a tumor suppressor, inactive in many tumors, and both GAS1 and PTEN inhibit the PI3K/AKT pathway. Therefore, it is relevant to investigate the potential additive effect of the overexpression of GAS1 and PTEN on tumor growth. In particular, we employed secreted forms of both GAS1 (tGAS1) and PTEN (PTEN-LONG, or PTEN-L) and tested their combined effect on glioma cells. We observed that the co-expression of both the proteins inhibited the growth of U-87 MG human glioblastoma cells more effectively than when independently expressed, and decreased the activity of both AKT and ERK1/2. Interestingly, the combination of the soluble forms was always the most effective treatment. To improve the transfer of tGAS1 and PTEN-L, we employed a lentiviral vector with a p2A peptide-enabled dual expression system that allowed the generation of the two proteins using a single promoter (CMV), in equimolar amounts. The viral vector reduced the growth of U-87 MG cells in vitro and had a striking effect in inhibiting their proliferation after inoculating it into the immunosuppressed mice. The present results support a potential adjuvant role for the combined use of tGAS1 and PTEN-L in the treatment of glioblastoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.
Natsume A, Yoshida J. Gene therapy for high-grade glioma: current approaches and future directions. Cell Adhes Migr. 2008;2:186–91.
Stupp R, Roila F. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:126–8.
Van Den Bent MJ, Weller M, Wen PY, Kros JM, Aldape K, Chang S. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol. 2017;19:614–24.
Louis DN, Holland EC, Cairncross JG. Glioma classification: a molecular reappraisal. Am J Pathol. 2001;159:779–86.
Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. 2017;19:v1–88.
Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004;6:227–35.
Benítez JA, Domínguez-Monzón G, Segovia J. Conventional and gene therapy strategies for the treatment of brain tumors. Curr Med Chem. 2008;15:729–42.
Segovia J, López-Ornelas A. Brain cancer, tumor targeting and cervical cancer. In: Hauppauge N, editor. Recent advances in glioma gene therapy. New York: Nova Science; 2011. pp. 201–16.
Park M, Seung-Koo L, Chang H, Kang G, Kim EU, Kim SH, et al. Elderly patients with newly diagnosed glioblastoma: can preoperative imaging descriptors improve the predictive power of a survival model? J Neurooncol. 2017;134:423–31.
Minniti G, Filippi AR, Osti MF, Ricardi U. Radiation therapy for older patients with brain tumors. Radiat Oncol. 2017;12:101.
Fine HA. New strategies in glioblastoma: exploiting the new biology. Clin Cancer Res. 2015;21:1984–8.
Sulman E, Aldape K, Colman H. Brain tumor stem cells. Curr Probl Cancer. 2008;32:124–42.
Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer. 2006;6:425–36.
Stebel M, Vatta P, Ruaro ME, Del Sal G, Parton RG, Schneider C. The growth suppressing gas1 product is a GPI-linked protein. FEBS Lett. 2000;481:152–8.
Zamorano A, Lamas M, Vergara P, Naranjo JR, Segovia J. Transcriptionally mediated gene targeting of gas1 to glioma cells elicits growth arrest and apoptosis. J Neurosci Res. 2003;71:256–63.
Zamorano A, Mellström B, Vergara P, Naranjo JR, Segovia J. Glial-specific retrovirally mediated gas1 gene expression induces glioma cell apoptosis and inhibits tumor growth in vivo. Neurobiol Dis. 2004;15:483–91.
Domínguez-Monzón G, Benítez JA, Vergara P, Lorenzana R, Segovia J. Gas1 inhibits cell proliferation and induces apoptosis of human primary gliomas in the absence of Shh. Int J Dev Neurosci. 2009;27:305–13.
López-Ramírez MA, Domínguez-Monzón G, Vergara P, Segovia J. Gas1 reduces Ret tyrosine 1062 phosphorylation and alters GDNF-mediated intracellular signaling. Int J Dev Neurosci. 2008;26:497–503.
Schueler-Furman O, Glick E, Segovia J, Linial M. Is GAS1 a co-receptor for the GDNF family of ligands? Trends Pharmacol Sci. 2006;27:72–7.
Sidorova YA, Saarma M. Glial cell line-derived neurotrophic factor family ligands and their therapeutic potential 1. Mol Biol. 2016;50:521–31.
Dominguez-Monzon G, Gonzalez-Ramirez R, Segovia J. Molecular mechanisms of action of Gas1 and its possible therapeutic applications. Curr Signal Transduct Ther. 2011;6:106–12.
Zarco N, González-Ramírez R, González RO, Segovia J. GAS1 induces cell death through an intrinsic apoptotic pathway. Apoptosis. 2012;17:627–35.
López-Ornelas A, Mejia-Castillo T, Vergara P, Segovia J. Lentiviral transfer of an inducible transgene expressing a soluble form of Gas1 causes glioma cell arrest, apoptosis and inhibits tumor growth. Cancer Gene Ther. 2011;18:87–99.
Jiménez A, López-Ornelas A, Estudillo E, González-Mariscal L, González RO, Segovia J. A soluble form of GAS1 inhibits tumor growth and angiogenesis in a triple negative breast cancer model. Exp Cell Res. 2014;327:307–17.
López-Ornelas A, Vergara P, Segovia J. Neural stem cells producing an inducible and soluble form of Gas1 target and inhibit intracranial glioma growth. Cytotherapy. 2014;16:1011–23.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate. Cancer Sci. 1997;275:1943–7.
Worby CA, Dixon JE. Pten. Annu Rev Biochem. 2014;83:641–69.
Planchon SM, Waite KA, Eng C. The nuclear affairs of PTEN. J Cell Sci. 2008;121:249–53.
Tachibana N, Cantrup R, Dixit R, Touahri Y, Kaushik G, Zinyk D, et al. Pten regulates retinal amacrine cell number by modulating Akt, Tgfβ, and Erk signaling. J Neurosci. 2016;36:9454–71.
Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN͞ MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase Akt pathway. Proc Natl Acad Sci USA. 1998;95:15587–91.
Stambolic V, Suzuki A, De PompaL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39.
Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.
Hopkins BD, Fine B, Steinbach N, Dendy M, Rapp Z, Shaw J, et al. A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science. 2013;341:399–402.
Malaney P, Uversky VN, Davé V. The PTEN long N-tail is intrinsically disordered: increased viability for PTEN therapy. Mol Biosyst. 2013;9:2877.
Putz U, Mah S, Goh CP, Low LH, Howitt J, Tan SS. PTEN secretion in exosomes. Methods. 2015;77-78:157–63.
Lu D-Y, Leung Y-M, Cheung C-W, Chen Y-R, Wong K-L. Glial cell line-derived neurotrophic factor induces cell migration and matrix metalloproteinase-13 expression in glioma cells. Biochem Pharmacol. 2010;80:1201–9.
Ryan MD, King AMQ, Thomas GP. Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol. 1991;72:2727–32.
Halpin C, Cooke SE, Barakate ElAmrani, Ryan MD. Self-processing 2A-polyproteins-a system for co-ordinate expression of multiple proteins in transgenic plants. Plant J. 1999;17:453–9.
De Felipe P, Luke GA, Hughes LE, Gani D, Halpin C, Ryan MD. E unum pluribus: multiple proteins from a self-processing polyprotein. Trends Biotechnol. 2006;24:68–75.
Garcia-Tovar CG, Perez A, Luna J, Mena R, Osorio B, Aleman V, et al. Biochemical and histochemical analysis of 71 kDa dystrophin isoform (Dp71f) in rat brain. Acta Histochem. 2001;103:209–24.
Wang H, Zhang P, Lin C, Yu Q, Wu J, Wang L, et al. Relevance and therapeutic possibility of PTEN-long in renal cell carcinoma. PLoS ONE. 2015;10:e114250.
Acknowledgements
We want to thank Araceli Navarrete for technical support and Rubén Sánchez for laboratory assistance. This work was partially supported by Conacyt (México) Grant 239516 (JS).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Sánchez-Hernández, L., Hernández-Soto, J., Vergara, P. et al. Additive effects of the combined expression of soluble forms of GAS1 and PTEN inhibiting glioblastoma growth. Gene Ther 25, 439–449 (2018). https://doi.org/10.1038/s41434-018-0020-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41434-018-0020-0
This article is cited by
-
A positive feedback loop between TAZ and miR-942-3p modulates proliferation, angiogenesis, epithelial-mesenchymal transition process, glycometabolism and ROS homeostasis in human bladder cancer
Journal of Experimental & Clinical Cancer Research (2021)
-
Viral vector: potential therapeutic for glioblastoma multiforme
Cancer Gene Therapy (2020)